tranexamic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2713	1197-18-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: tranexamic acid amchafibrin amikapron cyclocapron tranol transamin zataranax	Antifibrinolytic hemostatic used in severe hemorrhage. Molecular weight: 157.21 Formula: C8H15NO2 CLOGP: -1.80 LIPINSKI: 0 HAC: 3 HDO: 2 TPSA: 63.32 ALOGS: -0.94 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

tranexamic acid
amchafibrin
amikapron
cyclocapron
tranol
transamin
zataranax

Antifibrinolytic hemostatic used in severe hemorrhage.

Molecular weight: 157.21
Formula: C8H15NO2
CLOGP: -1.80
LIPINSKI: 0
HAC: 3
HDO: 2
TPSA: 63.32
ALOGS: -0.94
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
2	g	O
2	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Hosey CM, Chan R, Benet LZ
BA (Bioavailability)	34 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.38 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	2.40 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.97 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2.30 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 30, 1986	FDA	PHARMACIA AND UPJOHN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Purpura	83.90	17.37	39	8891	9872	50586322
Melaena	82.25	17.37	54	8876	26810	50569384
Pulmonary embolism	73.35	17.37	90	8840	101614	50494580
Renal cortical necrosis	72.22	17.37	13	8917	92	50596102
Wrong product administered	67.85	17.37	28	8902	5332	50590862
Vaginal haemorrhage	67.11	17.37	46	8884	24505	50571689
Heavy menstrual bleeding	62.09	17.37	37	8893	15500	50580694
Rash maculo-papular	56.96	17.37	43	8887	26598	50569596
Status epilepticus	56.39	17.37	33	8897	13373	50582821
Vasodilatation	50.84	17.37	18	8912	2261	50593933
Myoclonus	48.99	17.37	31	8899	14439	50581755
Haemorrhage	48.03	17.37	53	8877	53388	50542806
Thrombocytopenia	45.37	17.37	81	8849	127592	50468602
Rectal haemorrhage	45.02	17.37	44	8886	38514	50557680
Hereditary angioedema	44.77	17.37	21	8909	5421	50590773
Cerebral infarction	42.08	17.37	33	8897	21571	50574623
Deep vein thrombosis	42.08	17.37	58	8872	73246	50522948
Platelet count decreased	41.16	17.37	68	8862	100658	50495536
Biliary sepsis	40.74	17.37	12	8918	838	50595356
Generalised tonic-clonic seizure	40.40	17.37	35	8895	26275	50569919
Anaphylactic reaction	37.57	17.37	47	8883	54008	50542186
Aplastic anaemia	35.15	17.37	20	8910	7683	50588511
Acute left ventricular failure	32.50	17.37	10	8920	811	50595383
Tri-iodothyronine free decreased	31.94	17.37	8	8922	302	50595892
Infusion site scar	31.30	17.37	8	8922	328	50595866
Retinal artery occlusion	30.36	17.37	11	8919	1476	50594718
Fatigue	30.36	17.37	49	8881	707552	49888642
Rash erythematous	30.33	17.37	34	8896	34818	50561376
Epistaxis	29.99	17.37	46	8884	63908	50532286
Haemoglobin decreased	29.93	17.37	68	8862	127148	50469046
Brain oedema	28.74	17.37	21	8909	12349	50583845
Drug hypersensitivity	28.47	17.37	5	8925	251005	50345189
Basophil count increased	28.19	17.37	9	8921	823	50595371
Sepsis	27.95	17.37	68	8862	132857	50463337
Pain	27.82	17.37	37	8893	578866	50017328
Off label use	27.68	17.37	160	8770	474266	50121928
Incorrect route of product administration	26.98	17.37	24	8906	18642	50577552
Perforation	26.89	17.37	9	8921	955	50595239
Maternal exposure during delivery	26.52	17.37	9	8921	997	50595197
Product packaging confusion	26.18	17.37	6	8924	154	50596040
Ischaemic stroke	26.07	17.37	22	8908	15926	50580268
Circulatory collapse	25.56	17.37	24	8906	19976	50576218
Seizure	25.52	17.37	61	8869	117813	50478381
Joint swelling	25.51	17.37	6	8924	245280	50350914
Tonic clonic movements	24.70	17.37	9	8921	1228	50594966
Ureteric perforation	24.56	17.37	4	8926	14	50596180
Enterococcal sepsis	24.43	17.37	9	8921	1266	50594928
Neutropenic sepsis	24.13	17.37	20	8910	14127	50582067
Infusion site discomfort	23.71	17.37	8	8922	870	50595324
Abdominal discomfort	23.43	17.37	6	8924	231635	50364559
Infusion site warmth	23.40	17.37	9	8921	1425	50594769
Myoclonic epilepsy	22.89	17.37	8	8922	967	50595227
Alanine aminotransferase increased	22.76	17.37	49	8881	88310	50507884
Toxic epidermal necrolysis	22.72	17.37	23	8907	20969	50575225
Acute generalised exanthematous pustulosis	22.66	17.37	16	8914	8922	50587272
Product dose omission issue	22.35	17.37	3	8927	183835	50412359
Haemoptysis	22.34	17.37	25	8905	25548	50570646
Urine ketone body present	22.32	17.37	10	8920	2323	50593871
Meningitis aseptic	22.29	17.37	12	8918	4140	50592054
Hepatic function abnormal	22.04	17.37	28	8902	32653	50563541
Febrile neutropenia	21.63	17.37	51	8879	97616	50498578
Uterine haemorrhage	21.56	17.37	11	8919	3404	50592790
Drug intolerance	21.55	17.37	6	8924	219098	50377096
Embolic stroke	21.35	17.37	11	8919	3473	50592721
Product use in unapproved indication	20.96	17.37	56	8874	115763	50480431
Infusion site rash	20.40	17.37	8	8922	1334	50594860
Atrial thrombosis	19.66	17.37	8	8922	1469	50594725
Platelet count increased	19.65	17.37	18	8912	14522	50581672
PCO2 abnormal	19.49	17.37	4	8926	60	50596134
Nosocomial infection	19.42	17.37	8	8922	1514	50594680
Amylase increased	19.30	17.37	12	8918	5418	50590776
Hyperaesthesia	19.27	17.37	14	8916	8159	50588035
Blood pressure decreased	19.22	17.37	35	8895	55874	50540320
Stevens-Johnson syndrome	18.54	17.37	21	8909	21731	50574463
Cancer pain	18.29	17.37	9	8921	2578	50593616
Pyrexia	18.21	17.37	122	8808	380081	50216113
Multiple organ dysfunction syndrome	17.93	17.37	32	8898	50305	50545889
White blood cell count increased	17.88	17.37	29	8901	42211	50553983
HER2 positive breast cancer	17.62	17.37	5	8925	306	50595888

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myoclonus	77.28	17.89	44	6624	13265	29554594
Febrile neutropenia	74.54	17.89	108	6560	112132	29455727
Factor VIII inhibition	70.92	17.89	16	6652	296	29567563
Anaphylactic reaction	60.60	17.89	50	6618	27523	29540336
Generalised tonic-clonic seizure	57.99	17.89	42	6626	19097	29548762
Haemorrhage	51.62	17.89	57	6611	45015	29522844
Vasodilatation	47.86	17.89	15	6653	1009	29566850
Post procedural hypotension	42.56	17.89	8	6660	56	29567803
Platelet count decreased	40.28	17.89	79	6589	104593	29463266
Wrong product administered	34.69	17.89	18	6650	4513	29563346
Upper respiratory tract inflammation	33.82	17.89	13	6655	1607	29566252
Cerebral infarction	33.17	17.89	34	6634	24641	29543218
Interstitial lung disease	33.16	17.89	52	6616	57666	29510193
Haemoptysis	32.16	17.89	37	6631	30513	29537346
Mesenteric vascular insufficiency	31.98	17.89	7	6661	112	29567747
Haemoglobin increased	29.63	17.89	14	6654	2872	29564987
Muscle haemorrhage	27.60	17.89	14	6654	3348	29564511
Haemarthrosis	26.94	17.89	13	6655	2793	29565066
Haemophilia	26.35	17.89	4	6664	5	29567854
Hepatic function abnormal	24.83	17.89	37	6631	39222	29528637
Vascular stent thrombosis	24.78	17.89	12	6656	2598	29565261
Post procedural haemorrhage	23.96	17.89	17	6651	7474	29560385
Cerebral haemorrhage	23.38	17.89	32	6636	31394	29536465
Pneumonia	22.64	17.89	136	6532	320036	29247823
Myoclonic epilepsy	20.98	17.89	8	6660	967	29566892
Chronic pulmonary histoplasmosis	20.12	17.89	3	6665	3	29567856
Oesophageal haemorrhage	19.68	17.89	8	6660	1145	29566714
Myelodysplastic syndrome	19.48	17.89	22	6646	17772	29550087
Hepatic cyst ruptured	18.90	17.89	3	6665	6	29567853
Toxicity to various agents	18.52	17.89	8	6660	173653	29394206

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myoclonus	120.03	14.54	74	14896	25044	64458718
Wrong product administered	98.69	14.54	44	14926	7676	64476086
Generalised tonic-clonic seizure	97.71	14.54	78	14892	39779	64443983
Vasodilatation	94.87	14.54	33	14937	2985	64480777
Anaphylactic reaction	88.96	14.54	94	14876	68570	64415192
Haemorrhage	79.47	14.54	95	14875	79256	64404506
Platelet count decreased	70.88	14.54	134	14836	167577	64316185
Febrile neutropenia	67.33	14.54	140	14830	187517	64296245
Purpura	63.15	14.54	43	14927	17203	64466559
Cerebral infarction	60.03	14.54	60	14910	40984	64442778
Factor VIII inhibition	59.21	14.54	14	14956	311	64483451
Vaginal haemorrhage	58.69	14.54	43	14927	19301	64464461
Melaena	58.40	14.54	67	14903	53481	64430281
Renal cortical necrosis	55.28	14.54	13	14957	282	64483480
Status epilepticus	54.36	14.54	43	14927	21620	64462142
Pulmonary embolism	52.24	14.54	109	14861	146247	64337515
Heavy menstrual bleeding	51.21	14.54	33	14937	12044	64471718
Post procedural hypotension	47.62	14.54	9	14961	63	64483699
Haemoptysis	46.27	14.54	57	14913	48991	64434771
Myoclonic epilepsy	44.51	14.54	16	14954	1592	64482170
Fatigue	43.31	14.54	67	14903	748663	63735099
Toxicity to various agents	41.93	14.54	16	14954	363497	64120265
Aplastic anaemia	40.11	14.54	30	14940	13890	64469872
Hepatic function abnormal	38.47	14.54	60	14910	64253	64419509
Haemoglobin increased	37.37	14.54	20	14950	5181	64478581
Upper respiratory tract inflammation	37.26	14.54	18	14952	3764	64479998
Thrombocytopenia	36.01	14.54	124	14846	223677	64260085
Deep vein thrombosis	35.96	14.54	77	14893	105105	64378657
Incorrect route of product administration	33.95	14.54	34	14936	23264	64460498
Rash maculo-papular	32.58	14.54	47	14923	46979	64436783
Product packaging confusion	32.10	14.54	8	14962	223	64483539
Seizure	31.82	14.54	98	14872	166794	64316968
Biliary sepsis	31.41	14.54	12	14958	1416	64482346
Infusion site scar	31.01	14.54	8	14962	257	64483505
Mesenteric vascular insufficiency	30.40	14.54	7	14963	138	64483624
Cerebral haemorrhage	29.63	14.54	47	14923	51043	64432719
Rectal haemorrhage	29.35	14.54	52	14918	61765	64421997
Retinal artery occlusion	29.15	14.54	14	14956	2889	64480873
Tri-iodothyronine free decreased	28.56	14.54	8	14962	353	64483409
Hereditary angioedema	28.11	14.54	15	14955	3861	64479901
Muscle haemorrhage	27.59	14.54	17	14953	5736	64478026
Tonic clonic movements	27.56	14.54	12	14958	1977	64481785
Pain	26.99	14.54	55	14915	553456	63930306
Coronary artery thrombosis	26.30	14.54	13	14957	2856	64480906
Epistaxis	26	14.54	65	14905	98066	64385696
Blood pressure decreased	25.96	14.54	60	14910	86139	64397623
Rash erythematous	25.83	14.54	43	14927	48590	64435172
Haemoglobin decreased	25.42	14.54	101	14869	194962	64288800
Circulatory collapse	25.27	14.54	35	14935	33697	64450065
Maternal exposure during delivery	25.18	14.54	9	14961	881	64482881
Enterococcal sepsis	24.96	14.54	12	14958	2482	64481280
Weight decreased	24.92	14.54	18	14952	285721	64198041
Platelet count increased	24.91	14.54	26	14944	18670	64465092
Brain oedema	24.70	14.54	28	14942	22047	64461715
Acute left ventricular failure	24.69	14.54	10	14960	1377	64482385
Joint swelling	23.95	14.54	10	14960	215372	64268390
Drug intolerance	23.87	14.54	7	14963	187985	64295777
Post procedural haemorrhage	23.58	14.54	21	14949	12410	64471352
Infusion site warmth	23.55	14.54	9	14961	1063	64482699
Ureteric perforation	23.46	14.54	4	14966	14	64483748
Perforation	22.95	14.54	9	14961	1139	64482623
Infusion site discomfort	22.63	14.54	8	14962	758	64483004
Immune thrombocytopenia	21.97	14.54	22	14948	15044	64468718
Basophil count increased	21.86	14.54	9	14961	1291	64482471
Thoracotomy	21.69	14.54	5	14965	99	64483663
Uterine haemorrhage	21.62	14.54	11	14959	2568	64481194
Acute myocardial infarction	21.51	14.54	49	14921	69669	64414093
Interstitial lung disease	21.09	14.54	60	14910	97672	64386090
Haemorrhagic diathesis	20.78	14.54	14	14956	5500	64478262
Off label use	20.72	14.54	231	14739	632575	63851187
Alanine aminotransferase increased	20.58	14.54	75	14895	138956	64344806
Embolic stroke	20.54	14.54	15	14955	6696	64477066
Thrombotic microangiopathy	20.13	14.54	22	14948	16633	64467129
Chronic pulmonary histoplasmosis	20.03	14.54	3	14967	3	64483759
Infusion site rash	19.77	14.54	8	14962	1098	64482664
Myelodysplastic syndrome	19.74	14.54	28	14942	27551	64456211
Drug eruption	19.26	14.54	32	14938	36104	64447658
Haemarthrosis	19.05	14.54	13	14957	5216	64478546
Procedural haemorrhage	18.97	14.54	12	14958	4240	64479522
Vascular stent thrombosis	18.88	14.54	11	14959	3353	64480409
Hepatic cyst ruptured	18.81	14.54	3	14967	6	64483756
Neutropenic sepsis	18.72	14.54	25	14945	23247	64460515
Arthropathy	18.39	14.54	3	14967	120964	64362798
Acute myeloid leukaemia	18.37	14.54	27	14943	27436	64456326
Pyrexia	18.30	14.54	204	14766	558440	63925322
Drug hypersensitivity	18.23	14.54	17	14953	237798	64245964
PCO2 abnormal	18.22	14.54	4	14966	63	64483699
Abdominal discomfort	17.93	14.54	10	14960	182312	64301450
Multiple organ dysfunction syndrome	17.88	14.54	58	14912	101355	64382407
Intracardiac thrombus	17.70	14.54	11	14959	3770	64479992
Atrial thrombosis	17.22	14.54	10	14960	3032	64480730
Hyperaesthesia	17.20	14.54	16	14954	9998	64473764
Peripheral swelling	17.18	14.54	14	14956	209139	64274623
HER2 positive breast cancer	17.02	14.54	5	14965	262	64483500
Oesophageal haemorrhage	17.01	14.54	8	14962	1576	64482186
Pneumonia	16.83	14.54	201	14769	559375	63924387
Urine ketone body present	16.44	14.54	10	14960	3297	64480465
Aphasia	16.39	14.54	32	14938	40874	64442888
Anaphylactic shock	16.35	14.54	27	14943	30301	64453461
Cardiac failure congestive	16.32	14.54	5	14965	130575	64353187
Haemophilic arthropathy	16.24	14.54	4	14966	106	64483656
Bronchial artery embolisation	16.13	14.54	3	14967	19	64483743
Fibroma	15.91	14.54	6	14964	683	64483079
Product use in unapproved indication	15.90	14.54	82	14888	176536	64307226
Fall	15.90	14.54	47	14923	416779	64066983
Neutrophil count increased	15.76	14.54	24	14946	25150	64458612
Meningitis aseptic	15.73	14.54	12	14958	5718	64478044
White blood cell count increased	15.70	14.54	42	14928	65972	64417790
Sepsis	15.53	14.54	99	14871	230242	64253520
Weight increased	15.48	14.54	16	14954	213332	64270430
Pulmonary haemorrhage	15.30	14.54	17	14953	13092	64470670
Haemodynamic instability	15.15	14.54	18	14952	14894	64468868
Malignant neoplasm progression	15.14	14.54	59	14911	112812	64370950
Anaemia	15.09	14.54	144	14826	378536	64105226
Shock haemorrhagic	15.00	14.54	19	14951	16772	64466990

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	B02AA02	BLOOD AND BLOOD FORMING ORGANS ANTIHEMORRHAGICS ANTIFIBRINOLYTICS Amino acids
MeSH PA	D000933	Antifibrinolytic Agents
MeSH PA	D003029	Coagulants
MeSH PA	D006401	Hematologic Agents
MeSH PA	D006490	Hemostatics
FDA PE	N0000175632	Decreased Fibrinolysis
FDA EPC	N0000175634	Antifibrinolytic Agent
CHEBI has role	CHEBI:48675	antifibrinolytic agent
CHEBI has role	CHEBI:50248	hematologic agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Contraception	indication	13197004
Female hypogonadism syndrome	indication	16041008
Endometriosis	indication	129103003
Menorrhagia	indication	386692008
Hemorrhaging in Hemophilia	indication
Refractory melasma	off-label use	36209000
Epistaxis	off-label use	249366005
Hyperfibrinolysis Induced Hemorrhage	off-label use
Prevention of Hemorrhage with Cardiovascular Instability from Cardiopulmonary Bypass - CABG	off-label use
Postsurgical Hemorrhage	off-label use
Heart valve disorder	contraindication	368009	DOID:4079
Cerebral edema	contraindication	2032001
Hypercholesterolemia	contraindication	13644009
Subarachnoid intracranial hemorrhage	contraindication	21454007
Myocardial infarction	contraindication	22298006	DOID:5844
Depressive disorder	contraindication	35489007
Migraine	contraindication	37796009	DOID:6364
Hypertensive disorder	contraindication	38341003	DOID:10763
Disorder of gallbladder	contraindication	39621005	DOID:0060262
Body fluid retention	contraindication	43498006
Thrombosis of retinal vein	contraindication	46085004
Hyperlipidemia	contraindication	55822004	DOID:1168
Benign mammary dysplasia	contraindication	57993004
Obstructive hyperbilirubinemia	contraindication	59848001
Thrombophlebitis	contraindication	64156001	DOID:3875
Intermenstrual bleeding - irregular	contraindication	64996003
Cerebral arterial thrombosis	contraindication	71444005
Diabetes mellitus	contraindication	73211009	DOID:9351
Hyperglycemia	contraindication	80394007	DOID:4195
Malignant neoplasm of liver	contraindication	93870000	DOID:3571
Deep venous thrombosis	contraindication	128053003
Angina pectoris	contraindication	194828000
Impaired renal function disorder	contraindication	197663003
Cerebrovascular accident	contraindication	230690007
Pulmonary thromboembolism	contraindication	233935004
Thrombophilia	contraindication	234467004	DOID:2452
Disease of liver	contraindication	235856003	DOID:409
Cholestasis of pregnancy	contraindication	235888006
Endometrial carcinoma	contraindication	254878006	DOID:2871
Pregnancy, function	contraindication	289908002
Hypertriglyceridemia	contraindication	302870006
Malignant tumor of cervix	contraindication	363354003	DOID:4362
Thromboembolic disorder	contraindication	371039008
Cardiovascular event risk	contraindication	395112001
Ligneous conjunctivitis	contraindication	403435005
Disorder of coronary artery	contraindication	414024009
Obesity	contraindication	414916001	DOID:9970
Estrogen receptor positive tumor	contraindication	416053008
Porphyria	contraindication	418470004
Thrombosis	contraindication	439127006
Hypertensive urgency	contraindication	443482000
Carcinoma of female breast	contraindication	447782002
Smokes tobacco daily	contraindication	449868002
Major Surgery with Prolonged Post-Operative Immobilization	contraindication
Nonspecific Abnormal Papanicolaou Smear of Cervix	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.31	acidic
pKa2	10.7	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
650MG	LYSTEDA	AMRING PHARMS	N022430	Nov. 13, 2009	RX	TABLET	ORAL	8022106	March 4, 2025	TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING
650MG	LYSTEDA	AMRING PHARMS	N022430	Nov. 13, 2009	RX	TABLET	ORAL	8273795	March 4, 2025	TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING
650MG	LYSTEDA	AMRING PHARMS	N022430	Nov. 13, 2009	RX	TABLET	ORAL	8487005	March 4, 2025	TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING
650MG	LYSTEDA	AMRING PHARMS	N022430	Nov. 13, 2009	RX	TABLET	ORAL	8791160	March 4, 2025	TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING
650MG	LYSTEDA	AMRING PHARMS	N022430	Nov. 13, 2009	RX	TABLET	ORAL	8809394	March 4, 2025	TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING
650MG	LYSTEDA	AMRING PHARMS	N022430	Nov. 13, 2009	RX	TABLET	ORAL	8957113	March 4, 2025	TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Plasminogen	Enzyme	P00747	PLMN_HUMAN	INHIBITOR	Kd	5.96		CHEMBL	CHEMBL

External reference:

ID	Source
4020569	VUID
N0000148271	NUI
D01136	KEGG_DRUG
4020569	VANDF
C0040613	UMLSCUI
CHEBI:48669	CHEBI
CHEMBL877	ChEMBL_ID
DB00302	DRUGBANK_ID
D014148	MESH_DESCRIPTOR_UI
5526	PUBCHEM_CID
2060	INN_ID
6573	IUPHAR_LIGAND_ID
6T84R30KC1	UNII
10691	RXNORM
5607	MMSL
80873	MMSL
d00529	MMSL
002073	NDDF
109006003	SNOMEDCT_US
386960009	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Cyklokapron	HUMAN PRESCRIPTION DRUG LABEL	1	0013-1114	INJECTION, SOLUTION	100 mg	INTRAVENOUS	NDA	30 sections
Tranexamic Acid	HUMAN PRESCRIPTION DRUG LABEL	1	0517-0960	INJECTION, SOLUTION	100 mg	INTRAVENOUS	ANDA	30 sections
Tranexamic Acid	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3720	TABLET, FILM COATED	650 mg	ORAL	ANDA	25 sections
Tranexamic acid	HUMAN PRESCRIPTION DRUG LABEL	1	14789-500	INJECTION, SOLUTION	100 mg	INTRAVENOUS	ANDA	20 sections
Tranexamic Acid	HUMAN PRESCRIPTION DRUG LABEL	1	17478-017	INJECTION, SOLUTION	100 mg	INTRAVENOUS	ANDA	26 sections
Tranexamic Acid	HUMAN PRESCRIPTION DRUG LABEL	1	17478-018	INJECTION, SOLUTION	100 mg	INTRAVENOUS	ANDA	27 sections
Tranexamic Acid	HUMAN PRESCRIPTION DRUG LABEL	1	23155-166	INJECTION, SOLUTION	1 g	INTRAVENOUS	ANDA	24 sections
Tranexamic Acid	HUMAN PRESCRIPTION DRUG LABEL	1	23155-524	INJECTION, SOLUTION	1 g	INTRAVENOUS	ANDA	24 sections
Tranexamic Acid	HUMAN PRESCRIPTION DRUG LABEL	1	39822-1000	INJECTION, SOLUTION	100 mg	INTRAVENOUS	ANDA	29 sections
Tranexamic Acid	HUMAN PRESCRIPTION DRUG LABEL	1	42192-605	INJECTION, SOLUTION	100 mg	INTRAVENOUS	ANDA	13 sections
Tranexamic Acid	HUMAN PRESCRIPTION DRUG LABEL	1	42571-189	INJECTION	100 mg	INTRAVENOUS	ANDA	27 sections
TRANEXAMIC ACID	HUMAN PRESCRIPTION DRUG LABEL	1	42571-314	INJECTION	100 mg	INTRAVENOUS	ANDA	27 sections
TRANEXAMIC ACID	HUMAN PRESCRIPTION DRUG LABEL	1	43066-008	INJECTION	100 mg	INTRAVENOUS	ANDA	27 sections
Tranexamic Acid	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4530	INJECTION, SOLUTION	100 mg	INTRAVENOUS	ANDA	30 sections
tranexamic acid	HUMAN PRESCRIPTION DRUG LABEL	1	50090-5072	INJECTION, SOLUTION	100 mg	INTRAVENOUS	ANDA	26 sections
TRANEXAMIC ACID	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1532	INJECTION, SOLUTION	100 mg	INTRAVENOUS	ANDA	16 sections
TRANEXAMIC ACID IN SODIUM CHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	51754-0108	INJECTION, SOLUTION	10 mg	INTRAVENOUS	NDA	25 sections
Tranexamic Acid	Human Prescription Drug Label	1	55150-188	INJECTION, SOLUTION	100 mg	INTRAVENOUS	ANDA	27 sections
Lysteda	HUMAN PRESCRIPTION DRUG LABEL	1	55566-2110	TABLET	650 mg	ORAL	NDA	28 sections
Tranexamic Acid	HUMAN PRESCRIPTION DRUG LABEL	1	60505-3638	TABLET	650 1	ORAL	ANDA	25 sections
Tranexamic Acid	HUMAN PRESCRIPTION DRUG LABEL	1	60505-6169	INJECTION, SOLUTION	100 mg	INTRAVENOUS	ANDA	28 sections
Tranexamic Acid	HUMAN PRESCRIPTION DRUG LABEL	1	60505-6169	INJECTION, SOLUTION	100 mg	INTRAVENOUS	ANDA	28 sections
tranexamic acid	HUMAN PRESCRIPTION DRUG LABEL	1	61990-0611	INJECTION, SOLUTION	100 mg	INTRAVENOUS	ANDA	27 sections
Tranexamic Acid	HUMAN PRESCRIPTION DRUG LABEL	1	62559-265	TABLET	650 mg	ORAL	ANDA	29 sections
Tranexamic Acid	Human Prescription Drug Label	1	63323-563	INJECTION, SOLUTION	100 mg	INTRAVENOUS	ANDA	32 sections
Tranexamic Acid	Human Prescription Drug Label	1	63323-563	INJECTION, SOLUTION	100 mg	INTRAVENOUS	ANDA	32 sections
Tranexamic Acid	HUMAN PRESCRIPTION DRUG LABEL	1	63629-8599	TABLET, FILM COATED	650 mg	ORAL	ANDA	26 sections
Tranexamic Acid	HUMAN PRESCRIPTION DRUG LABEL	1	63629-8838	TABLET, FILM COATED	650 mg	ORAL	ANDA	26 sections
Tranexamic Acid	HUMAN PRESCRIPTION DRUG LABEL	1	63629-8838	TABLET, FILM COATED	650 mg	ORAL	ANDA	26 sections
Tranexamic Acid	Human Prescription Drug Label	1	65145-106	INJECTION	100 mg	INTRAVENOUS	ANDA	27 sections